McMullan Rowena L, Gordon Adrienne
Neonatology, Royal Prince Alfred Hospital, Sydney, NSW, Australia, 2050.
Cochrane Database Syst Rev. 2018 Mar 7;3(3):CD012181. doi: 10.1002/14651858.CD012181.pub2.
Late-onset sepsis is associated with increased rates of mortality and morbidity in newborn infants, in addition to poorer long-term developmental outcomes and increased length of stay and hospital costs. Central line-associated blood stream infection (CLABSI) is the most common cause of late-onset sepsis in hospitalised infants, and prevention of CLABSI is a key objective in neonatal care. Increased frequency of CLABSI around the time of removal of central venous catheters (CVCs) has been reported, and use of antibiotics at the time of removal may reduce the incidence and impact of late-onset sepsis in vulnerable newborn infants.
To determine the efficacy and safety of giving antibiotics at the time of removal of a central venous catheter (CVC) for reduction of morbidity and mortality in newborn infants, in particular effects on late-onset sepsis.
We used the standard search strategy of the Cochrane Neonatal Review Group without language restriction to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 3), MEDLINE via PubMed (1966 to 6 April 2017), Embase (1980 to 6 April 2017), and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982 to 6 April 2017). We also searched clinical trials databases, conference proceedings, and reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials.
Randomised, quasi-randomised, and cluster-randomised trials considering use of any antibiotic or combination of antibiotics at the time of CVC removal in newborn infants compared with placebo, no antibiotics, or another antibiotic or combination of antibiotics.
We extracted data using standard methods of the Cochrane Neonatal Review Group. Two review authors independently selected, assessed the quality of, and extracted data from the included study.
Only one randomised controlled trial was eligible for inclusion in this analysis. Forty-four of a total of 88 infants received two doses of cephazolin at the time of removal of CVC compared with no antibiotics at the time of removal of CVC in the control group. No infant in the intervention group developed late-onset sepsis after CVC removal compared with five of 44 (11%) in the control group (risk ratio (RR) 0.09, 95% confidence interval (CI) 0.01 to 1.60). Cephazolin given at the time of removal of CVC did not statistically significantly alter late-onset sepsis rates and led to no significant differences in any of the prespecified outcomes. Review authors judged the study to be of low quality because of high risk of bias and imprecision.
AUTHORS' CONCLUSIONS: Randomised controlled trials have provided inadequate evidence for assessment of the efficacy or safety of antibiotics given at the time of CVC removal. The single identified trial was underpowered to address this question. Future research should be directed towards targeting use of antibiotics upon removal of CVC for those at greatest risk of complications from CVC removal-related CLABSI. Researchers should include safety data such as impact upon antibiotic use and resistance patterns. This investigation would best occur as part of a bundle of quality improvement care interventions provided by neonatal networks.
晚发性败血症与新生儿死亡率和发病率增加相关,此外还会导致较差的长期发育结果、住院时间延长和住院费用增加。中心静脉导管相关血流感染(CLABSI)是住院婴儿晚发性败血症的最常见原因,预防CLABSI是新生儿护理的关键目标。据报道,在拔除中心静脉导管(CVC)前后CLABSI的发生频率会增加,在拔除时使用抗生素可能会降低脆弱新生儿晚发性败血症的发生率和影响。
确定在拔除中心静脉导管(CVC)时给予抗生素对降低新生儿发病率和死亡率的有效性和安全性,特别是对晚发性败血症的影响。
我们采用Cochrane新生儿综述小组的标准检索策略,无语言限制,检索Cochrane对照试验中心注册库(CENTRAL;2017年第3期)、通过PubMed检索MEDLINE(1966年至2017年4月6日)、Embase(1980年至2017年4月6日)以及护理和联合健康文献累积索引(CINAHL)(1982年至2017年4月6日)。我们还检索了临床试验数据库、会议论文集以及检索到的文章的参考文献列表,以查找随机对照试验和半随机试验。
随机、半随机和整群随机试验,比较在新生儿拔除CVC时使用任何抗生素或抗生素组合与安慰剂、不使用抗生素或其他抗生素或抗生素组合的情况。
我们使用Cochrane新生儿综述小组的标准方法提取数据。两位综述作者独立选择、评估纳入研究的质量并从中提取数据。
只有一项随机对照试验符合纳入本分析的条件。总共88名婴儿中有44名在拔除CVC时接受了两剂头孢唑林,而对照组在拔除CVC时未使用抗生素。干预组在拔除CVC后没有婴儿发生晚发性败血症,而对照组44名中有5名(11%)发生(风险比(RR)0.09,95%置信区间(CI)0.01至1.60)。拔除CVC时给予的头孢唑林在统计学上没有显著改变晚发性败血症的发生率,并且在任何预先设定的结局中均未导致显著差异。综述作者认为该研究质量较低,因为存在高偏倚风险和不精确性。
随机对照试验提供的证据不足以评估拔除CVC时给予抗生素的有效性或安全性。唯一确定的试验不足以解决这个问题。未来的研究应针对那些因拔除CVC相关CLABSI而发生并发症风险最高的人群,在拔除CVC时使用抗生素。研究人员应纳入安全数据,如对抗生素使用和耐药模式的影响。这项调查最好作为新生儿网络提供的一系列质量改进护理干预措施的一部分进行。